Evidence map›Paper›PMID 28241062›Full record

ArticlePloS one2017

Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.

Armin Birner, Martina Platzer, Susanne Astrid Bengesser, Nina Dalkner, Frederike T Fellendorf, Robert Queissner, Rene Pilz, Philipp Rauch, Alexander Maget, Carlo Hamm and 10 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 2 countries.

Armin BirnerDepartment for Psychiatry and Psychotherapy, Medical University of Graz, Graz, Austria.
Martina PlatzerDepartment for Psychiatry and Psychotherapy, Medical University of Graz, Graz, Austria.
Susanne Astrid BengesserDepartment for Psychiatry and Psychotherapy, Medical University of Graz, Graz, Austria.
Nina DalknerDepartment for Psychiatry and Psychotherapy, Medical University of Graz, Graz, Austria.
Frederike T FellendorfDepartment for Psychiatry and Psychotherapy, Medical University of Graz, Graz, Austria.
Robert QueissnerDepartment for Psychiatry and Psychotherapy, Medical University of Graz, Graz, Austria.
Rene PilzDepartment for Psychiatry and Psychotherapy, Medical University of Graz, Graz, Austria.
Philipp RauchDepartment for Psychiatry and Psychotherapy, Medical University of Graz, Graz, Austria.
Alexander MagetDepartment for Psychiatry and Psychotherapy, Medical University of Graz, Graz, Austria.
Carlo HammDepartment for Psychiatry and Psychotherapy, Medical University of Graz, Graz, Austria.
Simone Herzog-EberhardDepartment for Psychiatry and Psychotherapy, Medical University of Graz, Graz, Austria.
Harald ManggeClinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
Dietmar FuchsDivision of Biological Chemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Natalie MollInstitute of Laboratory Medicine, Medical Center of Munich University (LMU), Munich, Germany.
Sieglinde ZelzerClinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
Gregor SchützeInstitute of Laboratory Medicine, Medical Center of Munich University (LMU), Munich, Germany.
Markus SchwarzInstitute of Laboratory Medicine, Medical Center of Munich University (LMU), Munich, Germany.
Bernd ReininghausDepartment for Psychiatry and Psychotherapy, Medical University of Graz, Graz, Austria.
Hans-Peter KapfhammerDepartment for Psychiatry and Psychotherapy, Medical University of Graz, Graz, Austria.
Eva Z ReininghausDepartment for Psychiatry and Psychotherapy, Medical University of Graz, Graz, Austria.
Medical University of Graz · ATLudwig-Maximilians-Universität München · DEUniversität Innsbruck · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBipolar disorder (BD) is a chronic psychiatric disease which can take most different and unpredictable courses. It is accompanied by unspecific brainstructural changes and cognitive decline. The neurobiological underpinnings of these processes are still unclear. Emerging evidence suggests that tryptophan catabolites (TRYCATs), which involve all metabolites of tryptophan towards the kynurenine (KYN) branch, are involved in the etiology as well as in the course of BD. They are proposed to be mediators of immune-inflammation and neurodegeneration. In this study we measured the levels of KYN and its main catabolites consisting of the neurotoxic hydroxykynurenine (3-HK), the more neuroprotective kynurenic acid (KYNA) and anthranilic acid (AA) and evaluated the ratios between end-products and substrates as proxies for the specific enzymatic activity (3-HK/KYN, KYNA/KYN, AA/KYN) as well as 3-HK/KYNA as a proxy for neurotoxic vs. neuroprotective end-product relation in individuals with BD compared to healthy controls (HC).

methodsWe took peripheral TRYCAT blood levels of 143 euthymic to mild depressive BD patients and 101 HC. For statistical analyses MANCOVA's controlled for age, sex, body mass index, cardiovascular disease and smoking were performed.

resultsThe levels of KYNA (F = 5,579; p <.05) were reduced in BD compared to HC. The enzymatic activity of the kynurenine-3-monooxygenase (KMO) reflected by the 3-HK/KYN ratio was increased in BD individuals compared to HC (F = 5,394; p <.05). Additionally the ratio of 3-HK/KYNA was increased in individuals with BD compared to healthy controls (F = 11,357; p <.01). DISCUSSION: In conclusion our findings subserve the concept of KYN -pathway alterations in the pathophysiology of BD. We present evidence of increased breakdown towards the neurotoxic branch in KYN metabolism even in a euthymic to mild depressive state in BD. From literature we know that depression and mania are accompanied by inflammatory states which should be capable to produce an even greater imbalance due to activation of key enzymes in the neurotoxic direction of KYN -conversion. These processes could finally be involved in the development of unspecific brain structural changes and cognitive deficits which are prevalent in BD. Further research should focus on state dependent changes in TRYCATs and its relation to cognition, brain structure and staging parameters.

Indexed as

AdultBipolar DisorderBrainCase-Control StudiesCognitionDepressionFemaleHumansInflammationKynurenic AcidKynurenineMaleMiddle AgedMultivariate Analysisortho-AminobenzoatesQuinolinic Acidanthranilic acidKynurenic AcidKynurenineortho-AminobenzoatesQuinolinic AcidTryptophan

Identifiers

PMID28241062
PMCPMC5328271
OpenAlexW2592307528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.